Scaling Up for First Product Launch: Seven Hazards to Avoid Pierre Jacquet, M.D., Ph.D. Peter Rosenorn Aditya Natarajan Read more
Related Practice Life Sciences & Pharma As the margin for error in the drug launch cycle continues to erode, emerging biopharma companies face a growing urgency to double down on scaling up for that first launch. 01022024150106
Executive Insights Life Sciences & Pharma Launching Novel CDx for Oncology: 7 Strategies for Biopharma Companies April 17, 2025
Article Healthcare Services Healthcare Crossroads? The 2024 Election and What’s Really at Stake October 29, 2024
Published Articles Business Services What do leaders get wrong when making high-risk decisions? October 10, 2024
Executive Insights Life Sciences & Pharma Preparing for Innovation: A Maturity Framework for Artificial Intelligence in Life… August 2, 2024